Akt Signaling Pathway in Neurodegeneration

Overview

Akt (protein kinase B) is a serine/threonine kinase that plays a central role in cell survival, growth, metabolism, and synaptic plasticity. Akt serves as a critical downstream effector of phosphatidylinositol 3-kinase (PI3K) signaling and is a key mediator of neurotrophin-induced neuronal survival. Three isoforms of Akt exist—Akt1, Akt2, and Akt3—with distinct but overlapping expression patterns and functions in the nervous system^{1Altered insulin signaling in Alzheimer's disease brain — special emphasis on PI3K-Akt pathway2019 · Front Neurosci · DOI 10.3389/fnins.2019.00629Open reference}.

In the brain, Akt signaling is essential for neuronal development, synaptic plasticity, glucose metabolism, and protection against apoptotic cell death. Dysregulation of Akt signaling has been implicated in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), making it a major therapeutic target for neurodegenerative disorders^{2PI3K-PKB/Akt pathway2012 · Cold Spring Harb Perspect Biol · DOI 10.1101/cshperspect.a011189Open reference}.

Akt Isoforms

Akt1 (PKBα)

• Chromosome: 14q32.33

• Expression: Widely expressed in all tissues; highest in brain, heart, and skeletal muscle

• Primary function: General cell survival and growth; regulates angiogenesis

• Neurological role: Promotes neuronal survival; involved in learning and memory

Akt2 (PKBβ)

• Chromosome: 19q13.2

• Expression: Predominantly in insulin-responsive tissues (muscle, liver, fat)

• Primary function: Metabolic regulation, insulin signaling

• Neurological role: Brain insulin signaling; glucose metabolism in neurons

Akt3 (PKBγ)

• Chromosome: 1q43-q44

• Expression: Highest in brain and testis

• Primary function: Neuronal development; cognitive function

• Neurological role: Regulates brain size; involved in synaptic plasticity

Structure and Activation Mechanism

Domain Architecture

Akt contains three conserved domains^{3Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline2012 · J Clin Invest · DOI 10.1172/JCI59903Open reference}:

1. PH Domain (Pleckstrin Homology): N-terminal domain (aa 1-110) that binds phosphatidylinositol (3,4,5)-trisphosphate (PIP3), recruiting Akt to the plasma membrane

2. Kinase Domain (aa 111-408): Catalytic domain with an activation loop containing Thr308 (Akt1)

3. Hydrophobic Motif (HM): C-terminal regulatory domain containing Ser473

Activation Cascade

flowchart TD
    A["Growth Factor<br/>(Insulin/IGF-1/BDNF)"] --> B["Receptor Tyrosine Kinase"]
    B --> C["PI3K Activation"]
    C -->|"Phosphorylates PIP2"| D["PIP3 Generation"]
    D --> E["Akt Recruited to Membrane"]
    E -->|"PDK1"| F["Thr308 Phosphorylation"]
    E -->|"mTORC2"| G["Ser473 Phosphorylation"]
    F --> H["Fully Active Akt"]
    G --> H
    H --> I["GSK-3beta Inhibition"]
    H --> J["FOXO Inactivation"]
    H --> K["mTORC1 Activation"]
    H --> L["BAD Phosphorylation"]
    I --> M["Reduced Tau Phosphorylation"]
    J --> N["Anti-Apoptotic Gene Expression"]
    K --> O["Protein Synthesis"]
    L --> P["Cell Survival"]

    click A "/proteins/insulin-receptor"
    click I "/proteins/gsk3-beta"
    click M "/proteins/tau"

Activation Steps

1. Receptor activation: Insulin, IGF-1, BDNF, or NGF bind to their respective receptors (insulin receptor, TrkB, TrkA)

2. PI3K recruitment: Receptor activation recruits PI3K to the membrane

3. PIP3 generation: PI3K phosphorylates PIP2 to generate PIP3

4. Akt recruitment: Akt’s PH domain binds PIP3, localizing it to the membrane

5. Thr308 phosphorylation: PDK1 phosphorylates Akt at Thr308

6. Ser473 phosphorylation: mTORC2 phosphorylates Akt at Ser473 for full activation

Regulation of Akt Activity

Positive Regulators

Negative Regulators

Akt in Neuronal Function

Neuronal Survival

Akt promotes neuronal survival through multiple mechanisms^{4Akt and autophagy in neurodegenerative disease2022 · Cells · DOI 10.3390/cells11091495Open reference}:

1. GSK-3β inhibition: Akt phosphorylates GSK-3β at Ser9, inhibiting its activity. Since GSK-3β is the primary kinase responsible for tau hyperphosphorylation, Akt-mediated inhibition is neuroprotective

2. BAD inactivation: Akt phosphorylates BAD at Ser136, preventing it from inhibiting Bcl-xL and allowing mitochondrial outer membrane permeabilization

3. FOXO transcription factors: Akt phosphorylates FOXO1/3a, causing their nuclear export and preventing transcription of pro-apoptotic genes

4. NF-κB activation: Akt activates IKK, leading to NF-κB nuclear translocation and expression of anti-apoptotic genes

Synaptic Plasticity

Akt regulates synaptic plasticity through^{5The role of Akt in neuronal survival and degeneration2023 · Front Cell Neurosci · DOI 10.3389/fncel.2023.1152347Open reference}:

• AMPA receptor trafficking: Akt modulates AMPA receptor insertion into the postsynaptic membrane

• mTORC1 activation: Akt activates mTORC1, promoting local protein synthesis at synapses

• CREB activation: Akt phosphorylates and activates CREB, promoting transcription of plasticity-related genes

• Dendritic spine morphology: Akt signaling regulates spine formation and maintenance

Glucose Metabolism

In neurons, Akt regulates:

• GLUT3/4 translocation: Akt promotes glucose transporter insertion into the neuronal membrane

• Glycogen synthesis: Akt inhibits glycogen synthase, redirecting glucose to other pathways

• Mitochondrial function: Akt regulates mitochondrial biogenesis and function

Role in Alzheimer’s Disease

Brain Insulin Resistance

Akt signaling is impaired in Alzheimer’s disease through multiple mechanisms^{6The role of PI3K signaling pathway in Alzheimer's disease2024 · Front Aging Neurosci · DOI 10.3389/fnagi.2024.1459025Open reference}:

1. IRS-1 serine phosphorylation: In AD brain, IRS-1 is phosphorylated at inhibitory serine residues (Ser312, Ser616, Ser636), uncoupling insulin receptors from PI3K/Akt activation

2. Aβ interference: Amyloid-beta oligomers compete with insulin for insulin receptor binding and activate inflammatory pathways that suppress Akt signaling

3. Reduced Akt phosphorylation: Postmortem AD brain shows decreased Akt phosphorylation at both Thr308 and Ser473

Consequences of Akt Dysregulation

Therapeutic Implications

Restoring Akt signaling in AD is a major therapeutic strategy:

• Intranasal insulin: Activates brain insulin receptors and downstream Akt signaling

• GLP-1 receptor agonists: Promote Akt activation through insulin-independent mechanisms

• Akt activators: Direct Akt agonists in development

Role in Parkinson’s Disease

Dopaminergic Neuron Survival

Akt signaling is critical for dopaminergic neuron survival^{7Akt signaling in neuronal function and dysfunction2024 · Nat Rev Neurosci · DOI 10.1038/s41583-023-00759-8Open reference}:

1. LRRK2 interactions: LRRK2 G2019S mutations impair Akt signaling, reducing neuronal resilience

2. α-synuclein toxicity: Alpha-synuclein oligomers disrupt Akt signaling

3. Mitochondrial function: Akt regulates mitochondrial biogenesis and quality control

Therapeutic Strategies

• GDNF delivery: Promotes TrkB→PI3K→Akt signaling

• Akt pathway modulators: In development for PD

Role in Other Neurodegenerative Diseases

Huntington’s Disease

• Mutant huntingtin disrupts IRS-1/PI3K/Akt signaling

• Akt phosphorylation of huntingtin (Ser421) is neuroprotective

• Reduced BDNF signaling impairs Akt activation

Amyotrophic Lateral Sclerosis

• Mutant SOD1 interferes with Akt signaling

• IGF-1 delivery shows neuroprotective effects

Therapeutic Targeting

Akt Modulators in Development

Indirect Akt Activators

Clinical Translation and Therapeutic Implications

Current Therapeutic Approaches

Restoring or modulating Akt signaling represents a promising strategy for neurodegenerative disease modification. Several approaches are under investigation^{8Akt and autophagy interplay in neurodegeneration2022 · Autophagy · DOI 10.1080/15548627.2022.2056643Open reference}:

Direct Akt Modulators

While direct Akt inhibitors have been developed for cancer (perifosine, AZD5363), direct neuroprotective Akt activators remain in preclinical development. The challenge lies in achieving brain penetration while avoiding oncogenic effects. Current research focuses on:

• Isoform-selective modulators: Akt1 modulators for neuroprotection without affecting metabolic Akt2

• Allosteric activators: Targeting the PH domain to promote membrane localization

• Substrate-specific inhibitors: Avoiding direct kinase activation to reduce cancer risk

Indirect Akt Activators

Neurotrophic Factor Delivery

• GDNF: Promotes TrkB→PI3K→Akt signaling in dopaminergic neurons; gene therapy trials ongoing (NCT01621581)

• BDNF: Direct Akt activation; challenges with BBB penetration being addressed via intranasal delivery

• NRTN (Neurturin): AAV-mediated delivery to support dopaminergic neuron survival

Biomarker Development

Fluid Biomarkers

Imaging Biomarkers

Clinical Biomarkers Table

Clinical Trials Landscape

Active/Recent Trials Targeting Akt Pathway

Completed Key Trials

1. SPRINT-AD (Intranasal insulin): Showed improved cognition and CSF biomarkers

2. LIVE-DB (Liraglutide): Phase 2 trial in AD showing preserved glucose metabolism

3. PD GBA Gene Therapy (NCT03906042): AAV-GDNF delivery showing safety signals

Research Gaps

• No direct Akt activator trials in neurodegeneration: Cancer drugs too toxic for chronic use

• Limited biomarker validation: p-Akt measurements not standardized across labs

• Patient selection: No validated biomarkers to select patients most likely to respond

• Combination therapy: Trials needed combining Akt modulators with other mechanisms

Patient Impact

Alzheimer’s Disease

Akt pathway modulation may impact:

• Cognitive outcomes: Improved memory and executive function

• Disease progression: Slowed hippocampal atrophy

• Behavioral symptoms: Reduced agitation and psychosis

• Functional outcomes: Delayed loss of independence

Parkinson’s Disease

Akt-targeted therapies may provide:

• Motor symptoms: Improved motor UPDRS scores

• Non-motor symptoms: Potential cognitive benefits

• Disease modification: Slowed dopaminergic neuron loss

• Neuroprotective effects: Reduced progression rate

Amyotrophic Lateral Sclerosis

IGF-1/Akt pathway activation:

• Motor function: Potential preservation of muscle strength

• Survival: Possible extension of survival

• Respiratory function: Delayed respiratory decline

Challenges and Future Directions

Current Challenges

1. BBB penetration: Most large molecule Akt modulators cannot cross the BBB

2. Target engagement: No validated biomarker to confirm target engagement in humans

3. Therapeutic window: Balancing pathway activation with oncogenic risk

4. Isoform specificity: Achieving neuroprotective Akt1/Akt3 activation without metabolic Akt2 effects

5. Timing: Optimal intervention window in disease progression

6. Patient selection: Identifying patients with Akt pathway dysfunction

Future Directions

• Intranasal delivery: Bypassing BBB for peptide/growth factor delivery

• Brain-penetrant small molecules: Developing selective Akt activators without cancer risk

• Gene therapy: AAV-mediated delivery of Akt or upstream activators

• Biomarker-driven trials: Using p-GSK-3β or p-FOXO as enrollment or endpoint biomarkers

• Combination approaches: Akt modulation combined with anti-amyloid, anti-tau, or neuroinflammation targeting

• Precision medicine: Genotyping for PTEN variants or LRRK2 mutations to predict response

Emerging Therapeutic Targets

• PHLPP1 inhibitors: Enhancing Akt signaling by preventing dephosphorylation

• PTEN inhibitors: Restoring PI3K/Akt signaling (in development)

• mTORC2 activators: Upstream Akt activation

• IRS-1 serine phosphatase: Reducing inhibitory serine phosphorylation

See Also

• PI3K/Akt Signaling in Neurodegeneration

• GSK-3β Signaling Pathway

• mTOR Signaling in Neurodegeneration

• Alzheimer’s Disease

• Parkinson’s Disease

• Insulin Resistance in Alzheimer’s Disease

External Links

• PubMed - Biomedical literature

• Alzheimer’s Disease Neuroimaging Initiative - Research data

• Allen Brain Atlas - Brain gene expression data